Literature DB >> 6310037

Neuropathogenicity of herpes simplex virus in mice: protection against lethal encephalitis by co-infection with a non-encephalitogenic strain.

C H Schröder, G Kümel, J Glorioso, H Kirchner, H C Kaerner.   

Abstract

Intraperitoneal infection of susceptible mice with an apathogenic herpes simplex virus type 1 (HSV-1) strain prevented the lethal outcome of a challenge infection with a pathogenic strain, even if the challenge preceded the protective infection. It was found that the protective inoculation blocks the initial replication of the challenge virus. In addition, intraperitoneal infection with the protective HSV-1 strain led to the induction of a refractory state in the central nervous system, resulting in resistance to direct intracranial infection with HSV-1. This state is also inducible locally by intracerebral inoculation of a non-replicating mutant virus. The results indicate that HSV-1 strains differing in neurovirulence may differ in the induction or the sensitivity to this protective effect. Experiments with non-replicating HSV-1 temperature-sensitive strains demonstrated that protection against lethal infection does not depend on replication or expression of late genes of the protective strain. Inoculation of animals with detergent-soluble extracts of infected cells or infected and u.v.-irradiated syngeneic cells protected the animals against co-infection with encephalitogenic challenge virus. The experiments define this protective effect as an antigen-induced-immediate host defence mechanism active within 24 h post-infection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6310037     DOI: 10.1099/0022-1317-64-9-1973

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  5 in total

1.  Neurovirulence and latency in inbred mice of two HSV-1 intrastrain variants of divergent pathogenicity.

Authors:  G Kümel; C H Schröder; H C Kaerner
Journal:  Med Microbiol Immunol       Date:  1986       Impact factor: 3.402

2.  Neurovirulence of herpes simplex virus types 1 and 2 isolates in diseases of the central nervous system.

Authors:  T Bergström; K Alestig; B Svennerholm; P Horal; B Sköldenberg; A Vahlne
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-10       Impact factor: 3.267

3.  Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector.

Authors:  R Manservigi; M P Grossi; R Gualandri; P G Balboni; A Marchini; A Rotola; P Rimessi; D Di Luca; E Cassai; G Barbanti-Brodano
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

4.  Immunogenicity of herpes simplex virus glycoproteins gC and gB and their role in protective immunity.

Authors:  J Glorioso; C H Schröder; G Kumel; M Szczesiul; M Levine
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

5.  Herpes simplex virus type 1 long-term persistence, latency, and reactivation in infected Burkitt lymphoma cells.

Authors:  W Hampl; S Conrad; A K Kleinschmidt
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.